|Bid||24.50 x 800|
|Ask||26.73 x 1400|
|Day's range||26.14 - 27.31|
|52-week range||15.17 - 32.66|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||04 Nov 2020 - 09 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||26.28|
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Morgan Stanley 18th Annual Global Healthcare Conference on Tuesday, September 15, 2020. Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 2:00 p.m. EDT.
The acquisition of Bayer Animal Health establishes Elanco as the second-largest animal health company in the world.
Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has closed the acquisition of Bayer Animal Health. The transaction, valued at $6.89 billion, expands Elanco’s scale and capabilities, positioning the company for the long term as a leader in the attractive, durable animal health industry.